This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A rare genetic disorder kept her from even lifting her head. Then, months later, doctors delivered genetherapy directly to her brain. When Rylae-Ann Poulin was a year old, she didn’t crawl or babble like other kids her age. Read the rest…
Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its genetherapy SRP-9001 for Duchenne muscular dystrophy (DMD) in the next few months, with a view to making it available in sometime around the middle of 2023.
Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical genetherapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable genetherapy.
Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based genetherapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
It’s been a big week for cell and genetherapy approvals in the US, including a much-awaited approval for one to treat hemophilia A, the most common form of hemophilia. Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII).
In September 2021, GlobalData figures revealed there to be 1,320 industry-sponsored regenerative medicine and advanced therapy trials ongoing worldwide. Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications.
Whether catching up with relatives, attending a business meeting, or even visiting a doctor, it became commonplace to conduct this type of activity via a screen. Using patients’ genetic data. One of the largest companies in the genetic testing space, 23andMe, is also extremely active in healthcare. Tapping into data.
Scientists and doctors at University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) and Great Ormond Street Hospital (GOSH) have given hope of a genetherapy cure to children with a rare degenerative brain disorder called Dopamine Transporter Deficiency Syndrome (DTDS).
They had been modified in a lab by adding a functional gene to compensate for a defective one. Conner’s doctors expect that this groundbreaking genetherapy, which costs a staggering $3 million a patient, will stave off a fatal degenerative brain disease and save his life.
A doctor inserts the catheter through a small incision in a vein in the groin and guides it to the heart. The catheters tip is positioned at various locations within the heart, where the doctor uses a generator to deliver RF energy. Companion diagnostic for Pfizers hemophilia B genetherapy Beqvez (idanacogene elaparvovec-dzkt).
Many of the small challenges that face individual doctors and patients in seeking to find a solution for a rare disease also contribute to the difficulty of researching and developing an effective treatment. Once diagnosed, only 5% of rare diseases actually have an effective treatment. The outlook for rare disease R&D.
Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. Everyone’s genetic makeup differs, and each person’s cancer experience is unique to them – how cancer develops, how fast it spreads, which drugs it responds to, and more. Tailored oncology.
Wilson disease is a rare and progressive genetic condition in which the body’s process for removing excess copper is broken, allowing it to build to toxic levels and damage the liver, brain and other vital organs. Now, the data has been revealed – and according to investigators could transform treatment.
The vast majority of rare diseases have a genetic cause, with well-known examples including cystic fibrosis, sickle cell disease, Huntingdon’s, and various muscular atrophies and dystrophies. This often puts patients in difficult situations where they are passed between doctors until a correct diagnosis is reached.
Dr. Philipson’s transition to the biotech sector began with a position at UK-based biotech Trizell, where his efforts culminated in a genetherapy FDA submission for bladder cancer. Reflecting on the evolution of rare disease treatments, Dr. Philipson emphasizes the critical role of understanding disease biology and genetics.
For example, a LinkedIn article on the future of genetherapy can position a brand as an authority in genetic medicine, attracting biotech investors, researchers, and prescribing physicians. Doctor-patient interviews on managing chronic conditions. Behind-the-scenes research lab videos showcasing drug development.
Novartis’ Zolgensma (onasemnogene abeparvovec) genetherapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. Related: Is $2 Million Too Much For FDA-Approved SMA GeneTherapy? Zolgensma GeneTherapy: START Trial.
This meeting will host a panel of rare disease patients, caregivers, and advocates to have a focused discussion on the emerging field of genetherapy (regulated at the FDA by OTP). At least some (if not all) of the panelists will have had experience participating in genetherapy trials.
‘Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Genetherapy can ultimately only take you into the liver,” he explains.
Deloitte goes on to say “while biologics generally target smaller populations, “next-gen” therapies often target individual patients—sometimes as single treatments—resulting in truly personalized medicine. The cost is estimated to be in the billions.
In other cases, rare CNS conditions may be passed on from one generation to the next without knowledge or understanding that the reason for suffering or death among previous generations was genetic in basis and therefore identifiable, and perhaps even treatable. Doctors are often unfamiliar with these conditions.
In other areas of the industry (such as cell and genetic medicine development) progress continued at an impressively brisk pace despite the pandemic. Douglas Lee of Bayer Pharmaceuticals described this change as a major shift in how patients access healthcare and “a change in the mindset that you need to see the doctor for everything.”
I was recently reminded of my journey out of the HCT nightmare as I watched a documentary about genetherapy. Genetherapy is a huge deal – some genetherapies are already achieving jaw-dropping results for people with previously untreatable illnesses. It’s fascinating stuff. Yet lots of them don’t get HCT.
The companies include a diverse range engaged in innovative approaches in areas like oncology, genetic medicines, inflammatory diseases, dermatology and cardiorenal therapy. Check out this article to learn about the biotech companies that went public this year.
Another military man in the drugs business was Edward Robinson Squibb, who as a naval doctor during the Mexican-American war of 1846–1848 threw the drugs he was supplied with overboard due to their low quality. This knowledge of genetics and the underlying cause of many diseases, including cancer, has resulted in powerful new drugs.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content